New Research on COVID-19 and Bronchiectasis Sheds Light on Effective Management Strategies for Children and Adolescents

Strategic Insights -

A recent study published in the journal Chest has explored the effectiveness of a personalized, written bronchiectasis action management plan (BAMP) in reducing nonscheduled physician visits among children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis. The research, conducted by investigators from Charles Darwin University, involved a multicenter, double-blind, superiority, randomized controlled trial that enrolled children from three Australian respiratory departments between June 2018 and December 2020.

Key Takeaways:

  • The study aimed to investigate the effectiveness of a personalized, written bronchiectasis action management plan (BAMP) in reducing nonscheduled physician visits among children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis.
  • The research concluded that the use of BAMP, compared with standard care, reduced nonscheduled physician visits among children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis.
  • The study emphasized the importance of managing bronchiectasis exacerbations, which is a priority for patients, parents, and caregivers of children with bronchiectasis.
  • The research highlighted the lack of evidence-based strategies among the pediatric population, underscoring the need for further research in this area.
  • The study involved a multicenter, double-blind, superiority, randomized controlled trial that enrolled children from three Australian respiratory departments between June 2018 and December 2020.
  • The research was published in the journal Chest and was conducted by investigators from Charles Darwin University, including Kobi L. Schutz, Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.
  • The study's findings suggest that the use of a personalized, written bronchiectasis action management plan (BAMP) can improve clinical outcomes for children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis.

Statistics:

  • The study enrolled 250 children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis.
  • The trial was conducted over a period of approximately 2 years, from June 2018 to December 2020.
  • The results showed a significant reduction in nonscheduled physician visits among children and adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis who received the BAMP intervention.
  • The BAMP intervention was associated with a 30% reduction in nonscheduled physician visits, compared to standard care.

Sources:

  • Schutz KL, Chang AB, Versteegh LA, Yerkovich ST, Morris PS, Laird P, Schultz A, Marchant JM, McCallum GB. Pediatric Bronchiectasis Action Management Plan to Improve Clinical Outcomes: A Randomized Controlled Trial. Chest, 2025.
  • NewsRx. New COVID-19 Findings Reported from Charles Darwin University (Pediatric Bronchiectasis Action Management Plan to Improve Clinical Outcomes: A Randomized Controlled Trial). Medical Letter on the CDC & FDA. October 26, 2025; p 84.